We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The clinically available NMDA receptor antagonist, memantine, exhibits relative safety in the developing rat brain
- Authors
Manning, Simon M.; Boll, Griffin; Fitzgerald, Erin; Selip, Debra B.; Volpe, Joseph J.; Jensen, Frances E.
- Abstract
Abstract: The N-methyl-d-aspartate glutamate receptor (NMDAR) has been implicated in preterm brain injury (periventricular leukomalacia (PVL)) and represents a potential therapeutic target. However, the antagonist dizocilpine (MK-801) has been reported to increase constitutive neuronal apoptosis in the developing rat brain, limiting its clinical use in the developing brain. Memantine is another use-dependent NMDAR antagonist with shorter binding kinetics and has been demonstrated to be protective in a rat model of PVL, without effects on normal myelination or cortical growth. To further evaluate the safety of memantine in the developing brain, we demonstrate here that, in contrast to MK-801, memantine at neuroprotective doses does not increase neuronal constitutive apoptosis. In addition, there are no long-term alterations in the expression of NMDAR subunits, AMPAR subunits, and two markers of synaptogenesis, Synapsin-1 and PSD95. Evaluating clinically approved drugs in preclinical neonatal animal models of early brain development is an important prerequisite to considering them for clinical trial in preterm infants and early childhood.
- Subjects
METHYL aspartate; GLUTAMIC acid; LABORATORY rats; NEURAL development; APOPTOSIS; SYNAPSES
- Publication
International Journal of Developmental Neuroscience, 2011, Vol 29, Issue 7, p767
- ISSN
0736-5748
- Publication type
Article
- DOI
10.1016/j.ijdevneu.2011.05.005